S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:LGNDLigand Pharmaceuticals Stock Price, Forecast & News

$113.25
+0.05 (+0.04 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$110.69
Now: $113.25
$113.95
50-Day Range
$109.79
MA: $116.84
$126.72
52-Week Range
$57.24
Now: $113.25
$127.80
Volume146,125 shs
Average Volume415,046 shs
Market Capitalization$1.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.62
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Read More
Ligand Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.56 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120.28 million
Cash Flow$5.76 per share
Book Value$43.68 per share

Profitability

Net Income$629.30 million

Miscellaneous

Employees116
Market Cap$1.82 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$113.25
+0.05 (+0.04 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

How has Ligand Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Ligand Pharmaceuticals' stock was trading at $91.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LGND stock has increased by 23.3% and is now trading at $113.25.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Ligand Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Ligand Pharmaceuticals
.

When is Ligand Pharmaceuticals' next earnings date?

Ligand Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Ligand Pharmaceuticals
.

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings results on Monday, August, 3rd. The biotechnology company reported $1.00 earnings per share for the quarter, beating the consensus estimate of $0.76 by $0.24. The biotechnology company had revenue of $41.40 million for the quarter, compared to the consensus estimate of $29.96 million. Ligand Pharmaceuticals had a negative net margin of 19.51% and a positive return on equity of 4.41%. The business's revenue was up 65.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 earnings per share.
View Ligand Pharmaceuticals' earnings history
.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY20 earnings guidance on Monday, August, 3rd. The company provided EPS guidance of ~$4.10 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.71. The company issued revenue guidance of ~$165 million, compared to the consensus revenue estimate of $141.77 million.

What price target have analysts set for LGND?

7 brokerages have issued 12-month price objectives for Ligand Pharmaceuticals' shares. Their forecasts range from $145.00 to $229.00. On average, they expect Ligand Pharmaceuticals' share price to reach $179.75 in the next twelve months. This suggests a possible upside of 58.7% from the stock's current price.
View analysts' price targets for Ligand Pharmaceuticals
.

Has Ligand Pharmaceuticals been receiving favorable news coverage?

Headlines about LGND stock have trended somewhat negative on Friday, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Ligand Pharmaceuticals
.

Who are some of Ligand Pharmaceuticals' key competitors?

What other stocks do shareholders of Ligand Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Illumina (ILMN) and Cisco Systems (CSCO).

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the following people:
  • Mr. John L. Higgins, CEO & Exec. Director (Age 49)
  • Mr. Matthew W. Foehr, Pres & COO (Age 46)
  • Mr. Matthew Korenberg, Exec. VP of Fin. & CFO (Age 44)
  • Mr. Charles S. Berkman, Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Todd Pettingill, Director of Corp. Devel.

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Who are Ligand Pharmaceuticals' major shareholders?

Ligand Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.25%), William Blair Investment Management LLC (9.26%), Wasatch Advisors Inc. (6.05%), Conestoga Capital Advisors LLC (4.19%), Villere ST Denis J & Co. LLC (4.04%) and Knott David M (1.70%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Sunil Patel and Todd C Davis.
View institutional ownership trends for Ligand Pharmaceuticals
.

Which major investors are selling Ligand Pharmaceuticals stock?

LGND stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Vanguard Group Inc., Knott David M, Thrivent Financial for Lutherans, William Blair Investment Management LLC, Tygh Capital Management Inc., Gabelli Funds LLC, and Victory Capital Management Inc.. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, and Matthew W Foehr.
View insider buying and selling activity for Ligand Pharmaceuticals
.

Which major investors are buying Ligand Pharmaceuticals stock?

LGND stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Chicago Capital LLC, Granite Investment Partners LLC, Redwood Investments LLC, Nordea Investment Management AB, Pier Capital LLC, Prudential Financial Inc., and Principal Financial Group Inc.. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins, Matthew W Foehr, and Sunil Patel.
View insider buying and selling activity for Ligand Pharmaceuticals
.

How do I buy shares of Ligand Pharmaceuticals?

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of LGND stock can currently be purchased for approximately $113.25.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $1.82 billion and generates $120.28 million in revenue each year. The biotechnology company earns $629.30 million in net income (profit) each year or $2.11 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.

What is Ligand Pharmaceuticals' official website?

The official website for Ligand Pharmaceuticals is www.ligand.com.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.